TABLE 3.
Subgroup analyses for pooled analyses of survival by various time periods
| Baseline analyses | Sensitivity analyses# | |||||
| n | CSRs (95% CI) | I2 (%) | n | CSRs (95% CI) | I2 (%) | |
| 3-year CSRs | ||||||
| Overall | 59 | 61.8 (58.7–64.9) | 97.1 | 56 | 61.9 (58.7–65.1) | 97.2 |
| Before 2010 | 41 | 59.9 (55.8–64.1) | 95.8 | 41 | 59.9 (55.8–64.1) | 95.8 |
| 2010s | 18 | 66.2 (58.7–64.9) | 92.6 | 15 | 67.4 (63.9–70.9) | 93.1 |
| Test for difference¶ | p=0.067 | p=0.039 | ||||
| 5-year CSRs | ||||||
| Overall | 50 | 45.6 (41.5–49.7) | 97.7 | 47 | 45.9 (41.6–50.1) | 97.8 |
| Before 2010 | 36 | 44.1 (39.9–48.3) | 93.7 | 36 | 44.1 (39.9–48.3) | 93.7 |
| 2010s | 14 | 49.3 (42.7–49.7) | 97.7 | 11 | 51.4 (44.1–58.7) | 93.9 |
| Test for difference¶ | p=0.203 | p=0.106 | ||||
I2 >50% represents high between-studies heterogeneity. CSRs: cumulative survival rates; n: number of included studies. #: exclusion of three studies in which no patients received antifibrotics after year 2010; ¶: test for difference between subgroups (before 2010 versus 2010s).